Tumor Mutation Burden Normalization Using MAF Bins for Cell-Free DNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer detection methods using cell-free nucleic acids in bodily fluids face challenges due to low and variable nucleic acid amounts, complicating the comparison of tumor mutation burden (TMB) across samples, which affects the predictive value for immunotherapy responsiveness.
Innovation Solution
A method is developed to normalize TMB by determining the number of mutations and minor allele fraction in a test sample, comparing it to control samples within a bin of similar allele fractions, and calculating a Z-score to standardize the measurement, facilitating the identification of subjects likely to respond to immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cell-free nucleic acid testing is used for cancer detection, then non-invasive detection is achieved, but the low and variable amount of nucleic acids complicates TMB comparison across samples
Solution Approach 1:
The patent applies parameter changes by normalizing TMB measurements based on the minor allele fraction (MAF) parameter. By grouping samples into MAF bins and adjusting mutation counts according to these bins, the method compensates for variations in nucleic acid amount and quality, enabling accurate TMB comparison across different cell-free samples while maintaining the non-invasive detection advantage
2Reliability
If TMB is measured directly from cell-free nucleic acids, then immunotherapy prediction is possible, but variable nucleic acid recovery obscures predictive value
Solution Approach 1:
The patent implements feedback by using the minor allele fraction (MAF) as a quality control parameter that informs the normalization process. The MAF measurement feeds back into the TMB calculation by determining which normalization bin to apply, thereby compensating for variable nucleic acid recovery and improving both measurement consistency and immunotherapy prediction reliability
Data Source
AI summary
Values for tumor mutation burden from different samples can be made more comparable to each other or control standards by a normalization regime that takes into account the minor allele fraction of highly rated mutations in a sample. Such analysis can provide an indication where the tumor mutation burden of a test sample lies on a distribution of tumor mutation burdens in a control population, and thus, whether the individual providing the test sample is likely to be amenable to immunotherapy to treat cancer.